ContraFect Net Loss Reduced $CFRX $XHS

ContraFect Corporation, a Biotechnology firm, has announced its Annual results for the FY-2014.

The Results shows the following:-

Net loss Improved from -$10.8 to -$0.23, revenues over the year were $0 whereas General Expenses were reduced to $2.5 million from $49 Million Y/Y.

View the full earnings release here.